1836 U.S. Patent Office fire

Avesha's New Patent Sets the Stage for Next-Generation Kubernetes Multi-cluster and Multi-cloud Operations

Retrieved on:

Monday, October 2, 2023

1836 U.S. Patent Office fire, Patent, 3D printing, Mobile phone

CHELMSFORD, Mass., Oct. 2, 2023 /PRNewswire-PRWeb/ --

Key Points:

Boston-based technology startup Avesha Inc., an innovator in cloud infrastructure products specializing in automating, Kubernetes operations, is thrilled to announce the issuance of U.S. Patent No. 11,736,559 B2, titled "Providing a set of application slices within an application environment."

Robocast Defeats Google/YouTube's Attempts to Invalidate Robocast Smart Playlist Patents

Retrieved on:

Thursday, September 28, 2023

Robocast Inc., a leading innovator in playlist technology, announced today that it has successfully defended its U.S. Patent No.

Key Points:

Robocast Inc., a leading innovator in playlist technology, announced today that it has successfully defended its U.S. Patent No.
Google and YouTube join Netflix and Unified Patents in having institution denied in each of their IPRs.
All together, the PTAB denied institution on the merits of all eight IPR challenges against Robocast’s patents.
Robocast is represented by McKool Smith and Cantor Colburn in the IPR proceedings and the related district court litigation.

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

Retrieved on:

Tuesday, September 26, 2023

United States Patent and Trademark Office, 1836 U.S. Patent Office fire, Seizure, Patent, ECOR, ElectroCore, NVN, Use, 3D printing, Medical device

ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.

Key Points:

ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.
U.S. Patent No.
“We continue to broaden our intellectual property portfolio and strengthen our position around systems utilizing mobile devices to control stimulators,” stated Dan Goldberger, Chief Executive Officer of electroCore.
“The addition of this new patent is an example of how electroCore’s nVNS technology may be expanded in the future to cover neurological and psychiatric conditions, and how our robust patent portfolio covering the use of mobile devices to operate a nerve stimulator may be leveraged in our new suite of products and devices.”

SecureAuth Awarded New Patents for Identity Proofing

Retrieved on:

Wednesday, September 20, 2023

Software, Internet, Data Management, Wearables, Mobile Technology, Technology, Apps, Applications, Mobile, Wireless, Security, 1836 U.S. Patent Office fire, Patent, Organization, ID, Directory, Culture, Cryptocurrency

“SecureAuth is dedicated to protecting organizations from the onslaught of cybersecurity identity threats,” stated Paul Trulove, CEO of SecureAuth.

Key Points:

“SecureAuth is dedicated to protecting organizations from the onslaught of cybersecurity identity threats,” stated Paul Trulove, CEO of SecureAuth.
11,562,455, entitled “Method and system for identity verification and authorization of request by checking against an active user directory of identity service entities selected by an identity information owner” on January 24, 2023.
Methods disclosed in the patent include configuring specific authorization policies for an identity service provider such as a credit agency and allowing for an identity information request authorization by the identity owner.
Methods disclosed in the patent include performing entity authentication through identification (ID) proofing using both personal attributes and environmental information.

Attorneys from Houston's Susman Godfrey and Heim, Payne & Chorush Help Atlas Global Technologies Win $37.5 Million Patent Infringement Lawsuit

Retrieved on:

Friday, September 15, 2023

1836 U.S. Patent Office fire, LLP, United States Court of Appeals for the Federal Circuit, Atlas, Patexia, The ODP Corporation, Lawyer, Target, Hon, District court, Patent, Amazon (company), TP-Link, Douglas v. U.S. District Court ex rel Talk America, Tobacco, Network equipment provider, PLLC, Costco

MARSHALL, Texas, Sept. 15, 2023 /PRNewswire/ -- Trial lawyers from Houston's Susman Godfrey, LLP , and Heim, Payne & Chorush, LLP , have won a $37.5 million patent infringement verdict on behalf of Texas-based Atlas Global Technologies Inc. against China-based TP-Link Technologies Inc.

Key Points:

MARSHALL, Texas, Sept. 15, 2023 /PRNewswire/ -- Trial lawyers from Houston's Susman Godfrey, LLP , and Heim, Payne & Chorush, LLP , have won a $37.5 million patent infringement verdict on behalf of Texas-based Atlas Global Technologies Inc. against China-based TP-Link Technologies Inc.
Jurors issued the verdict following four days of trial by awarding the full amount Atlas Global's attorneys requested.
The lawsuit centered on TP-Link's infringement of eight Atlas Global patents covering an array of systems for transmitting information on wireless networks.
Heim, Payne & Chorush, LLP, represents plaintiffs and defendants in litigation across a broad range of technologies and business sectors.

Attorneys from Houston's Susman Godfrey and Heim, Payne & Chorush Help Atlas Global Technologies Win $37.5 Million Patent Infringement Lawsuit

Retrieved on:

Thursday, September 14, 2023

1836 U.S. Patent Office fire, LLP, United States Court of Appeals for the Federal Circuit, Stephen Susman, Atlas, Patexia, The ODP Corporation, Lawyer, Target, Hon, District court, Patent, Amazon (company), TP-Link, Douglas v. U.S. District Court ex rel Talk America, Tobacco, Network equipment provider, PLLC, Costco

MARSHALL, Texas, Sept. 14, 2023 /PRNewswire/ -- Trial lawyers from Houston's Susman Godfrey, LLP , and Heim, Payne & Chorush, LLP , have won a $37.5 million patent infringement verdict on behalf of Texas-based Atlas Global Technologies Inc. against China-based TP-Link Technologies Inc.

Key Points:

MARSHALL, Texas, Sept. 14, 2023 /PRNewswire/ -- Trial lawyers from Houston's Susman Godfrey, LLP , and Heim, Payne & Chorush, LLP , have won a $37.5 million patent infringement verdict on behalf of Texas-based Atlas Global Technologies Inc. against China-based TP-Link Technologies Inc.
Jurors issued the verdict following four days of trial by awarding the full amount Atlas Global's attorneys requested.
The Atlas Global trial team was led by the Susman Godfrey group, Heim, Payne & Chorush partners Michael Heim , Eric Enger , Alden Harris , and Blaine Larson , and partners Johnny Ward and Andrea Fair from Longview's Ward, Smith & Hill, PLLC .
The lawsuit centered on TP-Link's infringement of eight Atlas Global patents covering an array of systems for transmitting information on wireless networks.

Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent

Retrieved on:

Thursday, September 14, 2023

1836 U.S. Patent Office fire, Patent, Patient, United States Patent and Trademark Office, Physician, Standard of care, Bunion, United States patent law, Pharmaceutical industry, Treace Medical Concepts

“Our 50th U.S. Patent grant demonstrates our commitment to rapid and meaningful innovation that continues to set the standard in our field,” said John T. Treace, CEO, Founder and Board Member of Treace.

Key Points:

“Our 50th U.S. Patent grant demonstrates our commitment to rapid and meaningful innovation that continues to set the standard in our field,” said John T. Treace, CEO, Founder and Board Member of Treace.
“Our pioneering work in the bunion correction space dates back over nine years now.
Treace’s innovation continues to advance the standard of care in bunion correction and is recognized by the USPTO, along with patent offices around the world, as novel.
The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

Retrieved on:

Wednesday, August 30, 2023

1836 U.S. Patent Office fire, Patent, Orange, Teva, Justice, United States Department of Justice, Naltrexone, Federal Trade Commission, ALKS, Food and Drug Administration, Orange Book, Injunction, VIVITROL, District court, Alkermes, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Court, Douglas v. U.S. District Court ex rel Talk America, Generic drug

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension). Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No. 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.

Key Points:

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension).
Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No.
7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.
The company and Teva will submit the settlement agreement for review to the United States Federal Trade Commission and the United States Department of Justice.

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

Retrieved on:

Wednesday, August 30, 2023

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension). Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No. 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.

Key Points:

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension).
Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No.
7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.
The company and Teva will submit the settlement agreement for review to the United States Federal Trade Commission and the United States Department of Justice.

Axcella Granted Patent for Long COVID Fatigue Treatment

Retrieved on:

Tuesday, August 29, 2023

FDA, Health, Infectious Diseases, COVID-19, Pharmaceutical, Biotechnology, 1836 U.S. Patent Office fire, Patent, Senior, Fatigue, Dicarboxylic acid, Candidate, Patient, Biology, Therapy, PASC, NOS, Pharmaceutical industry

11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue.

Key Points:

11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue.
“Today’s issuance expands our global patent portfolio and Axcella’s protection of its lead candidate, AXA1125,” said Paul F. Fehlner, J.D., Ph.D., Senior Vice President, Chief Legal Officer of Axcella.
Axcella was previously granted patents related to AXA1125 with claims covering methods of use and compositions.
“We are pleased to have this additional designation as we pursue options to bring our investigational product forward for the benefit of the millions of people who continue to suffer from Long COVID Fatigue.